Viewing Study NCT00249860



Ignite Creation Date: 2024-05-05 @ 12:06 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00249860
Status: COMPLETED
Last Update Posted: 2013-08-06
First Post: 2005-11-04

Brief Title: A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
Sponsor: EMD Serono
Organization: EMD Serono

Study Overview

Official Title: A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
Status: COMPLETED
Status Verified Date: 2013-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main objective of this study is to establish interferon-beta-1a as the treatment of choice for chronic Hepatitis C with better efficacy and safety profiles in monotherapy or combination therapy

This will be a multicenter randomized double-blind placebo-controlled study with a placebo to be crossed-over to a combination of interferon-beta-1a and ribavirin or no treatment during an open-label extension phase The duration of the trial will be 48 weeks with a double-blind period of 12 weeks

The study will recruit 257 eligible subjects of either sex It will be conducted by approximately 16 Investigators investigational centers in 3 countries China Hong Kong and Singapore
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None